Qtrex Quantum Ltd. · NASDAQ:QTEX

Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (February 2024)

16 slides from Qtrex Quantum's investor presentation, Feb 27, 2024

  1. Slide 1: Investor Deck February 2024: Empowered Breathing Without Lungs

    Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 INVESTOR DECK I FEBRUARY 2024 EMPOWERED BREATHING WITHOUT LUNGS

  2. Slide 2: Forward-looking statements disclaimer

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 2 This presentation contains express or implied forward - looking statements pursuant to U . S . Federal securities laws . These forward - looking statements and their implications are

  3. Slide 3: Disclaimers and product status notes

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 3 • The reference to INSPIRA TM ART is a series of planned devices . The use of the term INSPIRA TM ART can refer to the INSPIRA TM ART 500 . INSPIRA TM ART 100 was previously known as

  4. Slide 4: Revolutionizing the $19 Billion Mechanical Ventilation Market

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 4 Inspira aims to revolutionize the $19 Billion Mechanical Ventilation Market We aspire waves of change in the world of life support Source: $19 Billion Predicted Global Mechanical Ven

  5. Slide 5: 20 Million Patients/Year on Mechanical Ventilation

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 5 See Disclaimers on slides 1 - 16 Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved ц 20 Million/Year on Mechanical Ventilation Source: ц 20M Patients/

  6. Slide 6: Patients can experience legacy complications from ventilation

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 6 Patients can often experience legacy complications: delirium, lung infections and injury or possible death! Patient under heavy sedation (COMA) with tube pushed down their throat Ven

  7. Slide 7: Oxygen straight into the blood

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 7 Oxygen Blood Body Organs Straight into the Blood Inspira

  8. Slide 8: INSPIRA ART: adaptive blood oxygenation with HYLA and VORTX

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 8 Designed to continuously measure the patient’s blood parameters in real - time, delivering needed oxygen volume straight into the blood o Proprietary HYLA o Proprietary VORTX Blood S

  9. Slide 9: We Aim to Prevent Mechanical Ventilation

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 9 Patient treated awake and without Mechanical Ventilation No Coma I No Tube in throat I Potentially reduces hospital days Oxygen is delivered straight into the blood, with carbon diox

  10. Slide 10: Inspira Patent Portfolio

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 10 VORTX - Orbiting blood oxygenation delivery system: A blood - gas exchange device and methods of use Dual lumen cannula and methods of use o Granted in the U.S., 2023 o Filed in Eur

  11. Slide 11: Our devices will revolutionize the medical landscape

    11 We believe our devices will revolutionize the medical landscape Gen 1 Blood Oxygenation (Cardio - Pulmonary Bypass) HYLA 1 Blood Sensor (Integrated with INSPIRA ART100) Gen 2 Adaptive Blood Oxygenation VORTX Orbiting Blood Oxygenation HYLA 2 Blood Sensor o Continuous blood monitoring o Real - tim

  12. Slide 12: Disrupting the Medical Landscape

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 12 Disrupting the Medical Landscape Tapping on strategic business opportunities $1 Billion Perfusion Systems Market $19 Billion Mechanical Ventilation Market INSPIRA ART100 Submitted t

  13. Slide 13: $546 Million in Pre-conditional Summary Distribution Agreements

    13 $546 Million in Pre - conditional Signed Summary Distribution Agreements Source: inspira - technologies.com/news/ While the Company intends to execute on the signed summary distribution agreements, there is no guarantee any sales will occur pursuant to the existing agreements. The potential pre -

  14. Slide 14: Team

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 14 Dr. Daniella Yeheskely - Hayon, PhD CTO Renowned Expert in the field of Artificial Lung Development Yafit Tehila, CPA CFO & Legal Serial Financial management experience in public co

  15. Slide 15: Intuition

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 15 INTUITION o Strong execution team o We believe there is a $19 billion market opportunity o FDA Clearance anticipated in H1 - 2024 for INSPIRA ART100 o Potential recurring revenue mo

  16. Slide 16: Thank You

    See Disclaimers on slides 1 - 16. Copyright © 2018 - 2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved 16 Inspira has a life print... Thank You

Inspira Technologies OXY B.H.N. — Investor Presentation (February 2024) on 6ix